Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1994 1
1995 19
1996 16
1997 9
1998 12
1999 17
2000 25
2001 18
2002 19
2003 23
2004 19
2005 26
2006 28
2007 27
2008 32
2009 31
2010 30
2011 47
2012 57
2013 71
2014 45
2015 46
2016 52
2017 40
2018 32
2019 42
2020 47
2021 47
2022 43
2023 37
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

889 results

Results by year

Filters applied: . Clear all
Page 1
Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management.
Huguet JM, Ferrer-Barceló L, Suárez P, Barcelo-Cerda S, Sempere J, Saracino IM, Fiorini G, Vaira D, Pérez-Aísa Á, Jonaitis L, Tepes B, Castro-Fernandez M, Pabón-Carrasco M, Keco-Huerga A, Voynovan I, Lucendo AJ, Lanas Á, Martínez-Domínguez SJ, Alfaro Almajano E, Rodrigo L, Vologzanina L, Bordin DS, Gasbarrini A, Babayeva G, Lerang F, Leja M, Kupčinskas J, Rokkas T, Marcos-Pinto R, Meštrović A, Gridnyev O, Phull PS, Smith SM, Boltin D, Buzás GM, Kral J, Şimşek H, Matysiak-Budnik T, Milivojevic V, Marlicz W, Venerito M, Boyanova L, Doulberis M, Capelle LG, Cano-Català A, Moreira L, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; Hp‐EuReg Investigators. Huguet JM, et al. Among authors: gisbert jp. United European Gastroenterol J. 2024 Apr 29. doi: 10.1002/ueg2.12569. Online ahead of print. United European Gastroenterol J. 2024. PMID: 38685613 Free article.
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α.
Spencer EA, Dubinsky MC, Kamm MA, Chaparro M, Gionchetti P, Rizzello F, Gisbert JP, Wright EK, Schulberg JD, Hamilton AL, McGovern DPB, Dervieux T. Spencer EA, et al. Among authors: gisbert jp. Front Immunol. 2024 Jan 23;15:1342477. doi: 10.3389/fimmu.2024.1342477. eCollection 2024. Front Immunol. 2024. PMID: 38476237 Free PMC article.
Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α.
Spencer EA, Dubinsky MC, Kamm MA, Chaparro M, Gionchetti P, Rizzello F, Gisbert JP, Wright EK, Schulberg JD, Hamilton AL, McGovern DPB, Dervieux T. Spencer EA, et al. Among authors: gisbert jp. Front Immunol. 2024 Feb 27;15:1383704. doi: 10.3389/fimmu.2024.1383704. eCollection 2024. Front Immunol. 2024. PMID: 38476224 Free PMC article.
Evaluation of genetic variants associated with the risk of thiopurine-related pancreatitis: a case control study from ENEIDA registry.
Guerra I, Barros F, Chaparro M, Benítez JM, Martín-Arranz MD, de Francisco R, Piqueras M, de Castro L, Carbajo AY, Bermejo F, Mínguez M, Gutiérrez A, Mesonero F, Cañete F, González-Muñoza C, Calvo M, Sicilia B, Alfambra E, Rivero M, Lucendo AJ, Tardillo CA, Almela P, Bujanda L, van Domselaar M, Ramos L, Fernández Sánchez M, Hinojosa E, Verdejo C, Gimenez A, Rodríguez-Lago I, Manceñido N, Pérez Calle JL, Moreno MDP, Delgado-Guillena PG, Antolín B, Ramírez de la Piscina P, Casanova MJ, Soto Escribano P, Martín Arranz E, Pérez-Martínez I, Mena R, García Morales N, Granja A, Boscá Watts MM, Francés R, Fernández C, Calafat M, Roig-Ramos C, Vera MI, Carracedo Á, Domènech E, Gisbert JP; ENEIDA Project of GETECCU. Guerra I, et al. Among authors: gisbert jp. Dig Dis. 2024 Mar 7. doi: 10.1159/000537782. Online ahead of print. Dig Dis. 2024. PMID: 38452742
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
García MJ, Riestra S, Amiot A, Julsgaard M, García de la Filia I, Calafat M, Aguas M, de la Peña L, Roig C, Caballol B, Casanova MJ, Farkas K, Boysen T, Bujanda L, Cuarán C, Dobru D, Fousekis F, Gargallo-Puyuelo CJ, Savarino E, Calvet X, Huguet JM, Kupcinskas L, López-Cardona J, Raine T, van Oostrom J, Gisbert JP, Chaparro M. García MJ, et al. Among authors: gisbert jp. Aliment Pharmacol Ther. 2024 May;59(10):1248-1259. doi: 10.1111/apt.17938. Epub 2024 Mar 6. Aliment Pharmacol Ther. 2024. PMID: 38445785
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
Allocca M, Catalano G, Savarino EV, Chaparro M, Levartovsky A, Michalopoulos G, Viazis N, Fousekis FS, Psistakis A, Noviello D, Nascimento CND, Caron B, Kitsou V, Bamias G, García MJ, Zacharopoulou E, Foteinogiannopoulou K, D'Amico F, Koutroubakis I, Ellul P, Tzouvala M, Peyrin-Biroulet L, Torres J, Caprioli F, Karmiris K, Theodoropoulou A, Katsanos KH, Christodoulou DK, Mantzaris GJ, Kopylov U, Gisbert JP, Danese S, Magro F, Carla F, Fiorino G. Allocca M, et al. Among authors: gisbert jp. United European Gastroenterol J. 2024 Feb 28. doi: 10.1002/ueg2.12492. Online ahead of print. United European Gastroenterol J. 2024. PMID: 38419274 Free article.
889 results